You can be on Entrepreneur’s cover!

This MIT Grad Is Changing Medicine With a Needle-Covered Pill Once he explains how it works, the idea is easy to swallow.

By Carly Okyle

entrepreneur daily

Opinions expressed by Entrepreneur contributors are their own.

Lemelson-MIT Program.

While medical injections are unpleasant and inconvenient, they're also necessary for people with illnesses like diabetes. But that might not be true for too much longer.

Carl Schoellhammer, 28, has created a pill that would render syringes unnecessary. A graduate student at MIT, he recently won $15,000 at the Lemelson-MIT National Collegiate Student Prize in the health-care category. "When I received the phone call [telling me I'd won], I made them tell me three times to make sure I wasn't dreaming," he says.

His prize-winning innovation is the Microneedle Pill (mPill), an ingestible capsule covered in microneedles -- that is, needles so small that they're measured in microns. The pill allows drugs that are typically injected to be delivered directly into the gastrointestinal tract.

Image credit: Lemelson-MIT Program.

Related: Google's Next Goal: Trying to Improve Robot-Assisted Surgery

"The GI tract is a dense network of blood capillaries," Schoellhammer explains. "The outer layer is a bit of a barrier so the needles are a nice way to introduce a drug into the tissue and then it diffuses and you get systemic delivery." In layman's terms: the drug gets into your system faster than it would if administered via injection.

Although an image of the pill that was used in testing might remind people of a cactus or a porcupine, the plan is for the pill to be smaller and coated when it hits the market. The coating will dissolve in stomach acid, freeing the needles to introduce the medicine. Once the drugs are delivered, the capsule can pass through the body safely. In the future, though, Schoellhammer hopes he can create the needles out of crystallized sugar.

The mPill took an estimated three years to go from concept to prototype, and it'll be approximately another three to five years before the product is on the market. In the meantime, the innovation has garnered attention. Schoellhammer says that he's in talks with with a few pharmaceutical companies about the mPill, and he hopes to market it as a diagnostic technology that can be used for a wide range of injections such as insulin and growth hormones. As it turns out, pharmaceutical giant Novartis announced this week that it's testing similar technology through a collaboration with a startup called Rani Therapeutics.

Related: The 10 Most Influential Leaders in Tech Right Now

Needle-covered pills aren't the only thing up Schoellhammer's sleeve. He's working on the Ultrasound Probe (uProbe), a handheld device inserted suppository-style that uses ultrasound waves to push medicine into the tissues of the GI tract. This allows the body to absorb the medicine faster.

Image credit: Lemelson-MIT Program.

Schoellhammer sees this being helpful for the 1 million people in the United States who have irritable bowel syndrome (IBS) as well as other conditions. While he wants to advance the uProbe further and conduct more animal testing, he estimates the product can be on the market in five years.

This is a lot of information to digest, but don't worry -- this brilliant scientist is probably already working on a way to make it easier.

Related: Meet Amelia, the AI Platform That Could Change the Future of IT

Carly Okyle

Assistant Editor, Contributed Content

Carly Okyle is an assistant editor for contributed content at

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Business News

James Clear Explains Why the 'Two Minute Rule' Is the Key to Long-Term Habit Building

The hardest step is usually the first one, he says. So make it short.


Get Your Business a One-Year Sam's Club Membership for Just $14

Shop for office essentials, lunch for the team, appliances, electronics, and more.

Business News

Microsoft's New AI Can Make Photographs Sing and Talk — and It Already Has the Mona Lisa Lip-Syncing

The VASA-1 AI model was not trained on the Mona Lisa but could animate it anyway.

Side Hustle

He Took His Side Hustle Full-Time After Being Laid Off From Meta in 2023 — Now He Earns About $200,000 a Year: 'Sweet, Sweet Irony'

When Scott Goodfriend moved from Los Angeles to New York City, he became "obsessed" with the city's culinary offerings — and saw a business opportunity.